$TOVX
Theriva Biologics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000141057824000601 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.467M $1.933M
YoY Change -45.46% -12.14%
% of Gross Profit
Research & Development $2.953M $3.459M
YoY Change -5.75% 16.19%
% of Gross Profit
Depreciation & Amortization $38.00K $39.00K
YoY Change 26.67% 21.88%
% of Gross Profit
Operating Expenses $8.488M $5.392M
YoY Change 45.84% 4.13%
Operating Profit -$8.488M -$5.392M
YoY Change 45.84% 4.13%
Interest Expense $172.0K $227.0K
YoY Change -54.74% -38.65%
% of Operating Profit
Other Income/Expense, Net $172.0K $227.0K
YoY Change -54.38% -38.65%
Pretax Income -$8.316M -$5.165M
YoY Change 52.78% 7.43%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$8.316M -$5.165M
YoY Change 63.06% 15.34%
Net Earnings / Revenue
Basic Earnings Per Share -$0.43 -$0.30
Diluted Earnings Per Share -$0.43 -$0.30
COMMON SHARES
Basic Shares Outstanding 17.28M 17.15M
Diluted Shares Outstanding 19.39M 17.15M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.59M $18.26M
YoY Change -51.55% -49.39%
Cash & Equivalents $16.60M $18.30M
Short-Term Investments
Other Short-Term Assets $1.192M $1.487M
YoY Change -65.25% -62.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables $171.0K $136.0K
Total Short-Term Assets $19.72M $21.66M
YoY Change -48.07% -46.26%
LONG-TERM ASSETS
Property, Plant & Equipment $336.0K $375.0K
YoY Change 11.63% 15.74%
Goodwill $1.465M $5.573M
YoY Change -73.94% -0.78%
Intangibles $19.18M $19.32M
YoY Change -1.56% -0.79%
Long-Term Investments
YoY Change
Other Assets $176.0K $176.0K
YoY Change 46.67% 46.67%
Total Long-Term Assets $22.68M $27.07M
YoY Change -17.5% -1.86%
TOTAL ASSETS
Total Short-Term Assets $19.72M $21.66M
Total Long-Term Assets $22.68M $27.07M
Total Assets $42.39M $48.73M
YoY Change -35.23% -28.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $935.0K $571.0K
YoY Change 26.18% 18.96%
Accrued Expenses $3.489M $3.327M
YoY Change 91.07% 60.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $62.00K $62.00K
YoY Change -11.43% -11.43%
Total Short-Term Liabilities $6.848M $6.009M
YoY Change -25.03% -30.28%
LONG-TERM LIABILITIES
Long-Term Debt $93.00K $159.0K
YoY Change -38.0% -0.63%
Other Long-Term Liabilities $7.803M $8.439M
YoY Change 4.6% 17.05%
Total Long-Term Liabilities $7.896M $8.598M
YoY Change 3.76% 16.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.848M $6.009M
Total Long-Term Liabilities $7.896M $8.598M
Total Liabilities $14.74M $14.61M
YoY Change -16.68% -15.57%
SHAREHOLDERS EQUITY
Retained Earnings -$322.8M -$314.5M
YoY Change 7.41% 6.45%
Common Stock $349.7M $346.7M
YoY Change 1.01% 0.82%
Preferred Stock
YoY Change
Treasury Stock (at cost) $288.0K $288.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $27.65M $34.12M
YoY Change
Total Liabilities & Shareholders Equity $42.39M $48.73M
YoY Change -35.23% -28.22%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$8.316M -$5.165M
YoY Change 63.06% 15.34%
Depreciation, Depletion And Amortization $38.00K $39.00K
YoY Change 26.67% 21.88%
Cash From Operating Activities -$3.452M -$4.881M
YoY Change -11.26% -12.99%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $0.00
YoY Change -90.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.000K $0.00
YoY Change -90.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.773M 0.000
YoY Change -17.15% -100.0%
NET CHANGE
Cash From Operating Activities -3.452M -4.881M
Cash From Investing Activities -1.000K 0.000
Cash From Financing Activities 1.773M 0.000
Net Change In Cash -1.680M -4.919M
YoY Change -4.55% -13.82%
FREE CASH FLOW
Cash From Operating Activities -$3.452M -$4.881M
Capital Expenditures $1.000K $0.00
Free Cash Flow -$3.453M -$4.881M
YoY Change -11.46% -13.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000894158
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y
CY2024Q1 tovx Lease Rent Abatement Period1
LeaseRentAbatementPeriod1
P3M
CY2024Q1 tovx Lessee Operating Lease Short Term Agreement Term
LesseeOperatingLeaseShortTermAgreementTerm
P90D
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-12584
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
33000
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
THERIVA BIOLOGICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3808303
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9605 Medical Center Drive, Suite 270
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
CY2024Q1 dei Entity Address Country
EntityAddressCountry
MD
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
CY2024Q1 dei City Area Code
CityAreaCode
301
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
417-4364
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
TOVX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17277371
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18261000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23177000
CY2024Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1772000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1812000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1623000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
21656000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
27403000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
99000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
102000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1634000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1759000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19316000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19755000
CY2024Q1 us-gaap Goodwill
Goodwill
5573000
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
CY2024Q1 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
77000
CY2023Q4 tovx Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
78000
CY2024Q1 us-gaap Assets
Assets
48730000
CY2023Q4 us-gaap Assets
Assets
55219000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
571000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
770000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3327000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2995000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
665000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2024Q1 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
886000
CY2023Q4 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
906000
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
62000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
487000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6009000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6738000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6476000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
6274000
CY2024Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
159000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2024Q1 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
664000
CY2023Q4 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
906000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1299000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1442000
CY2024Q1 us-gaap Liabilities
Liabilities
14607000
CY2023Q4 us-gaap Liabilities
Liabilities
15522000
CY2024Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17868282
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17148049
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17868282
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17148049
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
18000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
18000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346679000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
346519000
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
720233
CY2024Q1 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
288000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-537000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314483000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309318000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31389000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48730000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55219000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1933000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2201000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3459000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2977000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
5392000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
5178000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5392000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5178000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
228000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
364000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
227000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
370000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5165000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4808000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-330000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5165000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4478000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17148049
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17148049
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15124061
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15124061
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5165000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-569000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
374000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5734000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4104000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
36963000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
160000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
569000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5165000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31389000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
51830000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
126000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
-374000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
47852000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-5165000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4478000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
160000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
126000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-330000
CY2024Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
202000
CY2023Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
135000
CY2024Q1 tovx Non Cash Lease Expense
NonCashLeaseExpense
108000
CY2023Q1 tovx Non Cash Lease Expense
NonCashLeaseExpense
82000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000
CY2024Q1 tovx Increase Decrease In Deferred Research And Development Tax Credit
IncreaseDecreaseInDeferredResearchAndDevelopmentTaxCredit
-223000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-766000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
447000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-190000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-440000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
382000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
568000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-845000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-758000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-115000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-100000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4881000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5610000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
55000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-55000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-38000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-35000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4919000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5708000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23279000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41884000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18360000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36176000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18261000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36076000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18360000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36176000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314500000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18300000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375000
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 us-gaap Goodwill
Goodwill
5700000
CY2024Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-127000
CY2024Q1 us-gaap Goodwill
Goodwill
5573000
CY2024Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2024Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6476000
CY2023Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
6274000
CY2024Q1 tovx Deferred Research And Development Tax Credit Grant Receivable
DeferredResearchAndDevelopmentTaxCreditGrantReceivable
1800000
CY2024Q1 tovx Deferred Research And Development Tax Credit Current
DeferredResearchAndDevelopmentTaxCreditCurrent
886000
CY2024Q1 tovx Deferred Research And Development Tax Credit Noncurrent
DeferredResearchAndDevelopmentTaxCreditNoncurrent
664000
CY2024Q1 tovx Increase Decrease In Deferred Research And Development Tax Credit
IncreaseDecreaseInDeferredResearchAndDevelopmentTaxCredit
-223000
CY2024Q1 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
508000
CY2023Q4 tovx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
491000
CY2024Q1 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
364000
CY2023Q4 tovx Prepaid Clinical Research Organizations Expense Current
PrepaidClinicalResearchOrganizationsExpenseCurrent
1119000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
337000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
496000
CY2024Q1 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
278000
CY2023Q4 tovx Prepaid Consulting Subscriptions And Other Expenses
PrepaidConsultingSubscriptionsAndOtherExpenses
180000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
136000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
128000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1623000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2414000
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1412000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1424000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1037000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1002000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
422000
CY2024Q1 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
2424000
CY2023Q4 tovx Accrued Clinical Consulting Services
AccruedClinicalConsultingServices
1700000
CY2024Q1 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
593000
CY2023Q4 tovx Accrued Manufacturing Costs
AccruedManufacturingCosts
843000
CY2024Q1 tovx Accrued Vendor Payments
AccruedVendorPayments
310000
CY2023Q4 tovx Accrued Vendor Payments
AccruedVendorPayments
452000
CY2024Q1 tovx Accrued Expenses
AccruedExpenses
3327000
CY2023Q4 tovx Accrued Expenses
AccruedExpenses
2995000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
325000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1307000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
224000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
127000
CY2024Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
115000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
83000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
665000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1517000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1100000
CY2018Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18600000
CY2023 tovx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2024Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
159000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
63000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
162000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
53000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
62000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
64000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
634426
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.22
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y9M10D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
634426
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.22
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5200000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4500000
CY2022Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
8.00
CY2022Q3 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000000.0
CY2022Q3 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
1.22
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2459016
CY2022Q3 tovx Votes Relating To Preferred Stock
VotesRelatingToPreferredStock
1549295
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
99000
CY2024Q1 us-gaap Loans Payable Current
LoansPayableCurrent
62000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
9000
CY2024Q1 tovx Long Term Debt.
LongTermDebt.
221000
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P63M
CY2024Q1 tovx Percentage Of Office Leases Owned By Subsidiary
PercentageOfOfficeLeasesOwnedBySubsidiary
1
CY2024Q1 tovx Lessee Operating Lease Additional Renewal Term
LesseeOperatingLeaseAdditionalRenewalTerm
P5Y
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
158000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
144000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
937000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
497000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
673000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
588000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
368000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2126000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
329000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1797000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
498000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1299000

Files In Submission

Name View Source Status
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
0001410578-24-000601-index-headers.html Edgar Link pending
0001410578-24-000601-index.html Edgar Link pending
0001410578-24-000601.txt Edgar Link pending
0001410578-24-000601-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240331.xsd Edgar Link pending
tmb-20240331x10q.htm Edgar Link pending
tmb-20240331x10q001.jpg Edgar Link pending
tmb-20240331xex31d1.htm Edgar Link pending
tmb-20240331xex32d1.htm Edgar Link pending
tmb-20240331x10q_htm.xml Edgar Link completed
tmb-20240331_cal.xml Edgar Link unprocessable
tmb-20240331_def.xml Edgar Link unprocessable
tmb-20240331_lab.xml Edgar Link unprocessable
tmb-20240331_pre.xml Edgar Link unprocessable